68Ga-PSMA PET/CT与多参数MRI对低危和中危前列腺癌检出能力的比较
该回顾性分析纳入2019年6月至2021年3月间接受前列腺活检和/或根治性前列腺切除术、并同时行68Ga-PSMA PET/CT与mpMRI扫描的101例病理确诊前列腺癌患者,按D'Amico分类分层比较两种影像的检出率。在高危队列中68Ga-PSMA PET/CT阳性率高于mpMRI(64/66,97.0% vs 58/66,87.9%,p<0.05),而在低危和中危队列中mpMRI诊断信心更优(30/35,85.7% vs 21/35,60.0%,p<0.05)。
要点
- 高危前列腺癌中68Ga-PSMA PET/CT检出率97.0%(64/66)高于mpMRI的87.9%(58/66),p<0.05。
- 低危和中危前列腺癌中mpMRI检出率85.7%(30/35)高于68Ga-PSMA PET/CT的60.0%(21/35),p<0.05。
- 年龄≥62.5岁且血清PSA≥9.4 ng/ml的低危和中危患者病变更易出现PSMA高摄取。
核心结论
- 在高危前列腺癌队列中68Ga-PSMA PET/CT的诊断性能优于mpMRI,与既往研究一致。
- 在低危和中危前列腺癌的初始诊断中,mpMRI的诊断准确性高于68Ga-PSMA PET/CT。
- PSA≥9.4 ng/ml且年龄≥62.5岁的低危和中危前列腺癌患者更可能出现68Ga-PSMA PET/CT阳性结果。
研究设计与样本
- 回顾性分析2019年6月至2021年3月期间接受前列腺活检和/或根治性前列腺切除术、并接受68Ga-PSMA PET/CT和mpMRI扫描的患者。
- 共分析101例病理确诊为前列腺癌的患者,按D'Amico分类分层并结合临床数据进行分层分析。
- mpMRI图像采用前列腺影像报告和数据系统第2.1版(PI-RADS)评分,分为阴性(PI-RADS 1-3)或阳性(PI-RADS 4-5)。
- 68Ga-PSMA PET/CT可疑病灶由双培训认证的核医学医师审阅分类,结果与组织病理学结果对照评估。
主要发现
- 101例患者中88例(80.6%)mpMRI结果为病理阳性,85例(79.1%)68Ga-PSMA PET/CT结果为病理阳性。
- 高危前列腺癌队列中68Ga-PSMA PET/CT阳性64/66(97.0%),高于mpMRI的58/66(87.9%),p<0.05。
- 低危和中危前列腺癌中mpMRI诊断信心更优,检出30/35(85.7%),高于68Ga-PSMA PET/CT的21/35(60.0%),p<0.05。
- 年龄阈值超过62.5岁且血清PSA阈值超过9.4 ng/ml时,低危和中危前列腺癌病灶更易出现PSMA高摄取。
关键数值与推荐
- mpMRI阳性定义为PI-RADS 4-5,阴性定义为PI-RADS 1-3。
- 高危前列腺癌:68Ga-PSMA PET/CT阳性64/66(97.0%)vs mpMRI阳性58/66(87.9%),p<0.05。
- 低危和中危前列腺癌:mpMRI阳性30/35(85.7%)vs 68Ga-PSMA PET/CT阳性21/35(60.0%),p<0.05。
- 低危和中危前列腺癌PSMA高摄取的年龄阈值为62.5岁、血清PSA阈值为9.4 ng/ml。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess 68Ga-PSMA PET/CT for detection of low- and intermediate-risk prostate cancer (PCa), high-risk PCa in comparison with mpMRI, respectively, and to determine which of low- and intermediate-risk PCa are more likely to be detected by 68Ga-PSMA PET/CT. METHODS: We conducted a retrospective analysis of patients who had undergone a prostate biopsy and/or radical prostatectomy and who were scanned with 68Ga-PSMA PET/CT and mpMRI between June 2019 and March 2021. The mpMRI images were scored with the Prostate Imaging-Reporting and Data System Version 2.1 (PI-RADS) and were classified as either negative (PI-RADS 1-3) or positive (PI-RADS 4-5). Suspicious 68Ga-PSMA PET/CT lesions were reviewed for each relevant patient and classified by double-trained board-certified nuclear medicine physicians. The results were evaluated with the histopathological outcome. All patients were classified according to the D'Amico classification, and the clinical data were combined for stratified analysis. RESULT: A total of 101 patients who were pathologically diagnosed with PCa were analyzed. Of the 101 patients, 88 (80.6%) patients presented with a pathologic mpMRI, and 85 (79.1%) with a pathologic 68Ga-PSMA PET/CT. In the high-risk PCa cohort, 68Ga-PSMA PET/CT was positive in 64/66 (97.0%) patients and yielded a higher detection rate than that for the mpMRI patients (58/66, 87.9%; p < 0.05). However, mpMRI provided superior diagnostic confidence in identifying low- and intermediate-risk PCa (30/35, 85.7% vs. 21/35, 60.0%; p < 0.05). When the age threshold exceeded 62.5 years and the serum prostate specific antigen (PSA) threshold exceeded 9.4 ng/ml, a higher uptake of PSMA was more likely to occur in the lesions of low- and intermediate-risk PCa. CONCLUSION: The diagnostic performance of 68Ga-PSMA PET/CT was superior to that of mpMRI in the high-risk PCa cohort, which was consistent with prior studies. Furthermore, in the initial diagnosis of low- and intermediate-risk PCa, we found that mpMRI showed a higher diagnostic accuracy than 68Ga-PSMA PET/CT did. Low- and intermediate-risk PCa patients with a PSA ≥ 9.4 ng/ml and age ≥ 62.5 years were more likely to have a positive 68Ga-PSMA PET/CT result.
引用
- Zhou C, Tang Y, Deng Z, et al. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer. EJNMMI Res. 2022. PMID: 35147810. doi:10.1186/s13550-022-00881-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。